Cargando…
Orexin 2 receptor–selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients
Narcolepsy type 1 (NT1) is a sleep disorder caused by a loss of orexinergic neurons. Narcolepsy type 2 (NT2) is heterogeneous; affected individuals typically have normal orexin levels. Following evaluation in mice, the effects of the orexin 2 receptor (OX2R)-selective agonist danavorexton were evalu...
Autores principales: | Evans, Rebecca, Kimura, Haruhide, Alexander, Robert, Davies, Ceri H., Faessel, Hélène, Hartman, Deborah S., Ishikawa, Takashi, Ratti, Emiliangelo, Shimizu, Kohei, Suzuki, Motohisa, Tanaka, Shinichiro, Yukitake, Hiroshi, Dauvilliers, Yves, Mignot, Emmanuel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436334/ https://www.ncbi.nlm.nih.gov/pubmed/35994639 http://dx.doi.org/10.1073/pnas.2207531119 |
Ejemplares similares
-
Safety and pharmacodynamics of a single infusion of danavorexton in adults with idiopathic hypersomnia
por: Mignot, Emmanuel, et al.
Publicado: (2023) -
Narcolepsy and Orexins: An Example of Progress in Sleep Research
por: De la Herrán-Arita, Alberto K., et al.
Publicado: (2011) -
Recent advances in treatment for narcolepsy
por: Barateau, Lucie, et al.
Publicado: (2019) -
Discovery of TAK-925 as a Potent, Selective, and Brain-Penetrant
Orexin 2 Receptor Agonist
por: Fujimoto, Tatsuhiko, et al.
Publicado: (2022) -
The relationship between orexin levels and blood pressure changes in patients with narcolepsy
por: Sieminski, Mariusz, et al.
Publicado: (2017)